Introduction
============

Radical prostatectomy (RP) is the treatment of choice for patients with localized prostate cancer. Despite advances in pelvic anatomy and surgical technique, the overall incidence of post RP incontinence continues to rise due to the increasing numbers of RP performed ([@r1],[@r2]). Currently the prevalence of post-prostatectomy incontinence (PPI) varies from 1% to 87%, depending on the definition, timing of evaluation, surgical approach and who carries out the assessment ([@r3]-[@r5]). PPI is multi-factorial and is due to intrinsic sphincter deficiency (ISD) and to pre-existing bladder dysfunction or dysfunction arising *de novo* post RP ([@r6]-[@r8]). [*Table 1*](#t1){ref-type="table"} shows studies reporting the cause of PPI. ISD is considered to be the most important and most common contributing factor to PPI; however detrusor overactivity (DO), detrusor underactivity (DU) and poor bladder compliance commonly occur with ISD or in isolation, and are important factors in PPI ([@r12]).

###### Etiology of post prostatectomy incontinence (PPI)

  Study                                     Total N   SUI (%)   DO (%)          DU (%)          PC (%)
  ----------------------------------------- --------- --------- --------------- --------------- --------
  Hellström *et al.*, \[1989\] ([@r9])      19        --        --              19              --
  Presti Jr *et al.*, \[1990\] ([@r10])     24        25        --              --              --
  Foote *et al.*, \[1991\] ([@r11])         71        --        --              --              7
  26                                        33        --        --              --              
  Groutz A *et al.*, \[2000\] ([@r12])      83        32        4               1.2             82
  Chao *et al.*, \[1995\] ([@r7])           74        --        4               --              42
  Goluboff *et al.*, \[1995\] ([@r13])      25        8         40              --              8
  Leach *et al.*, \[1996\] ([@r14])         25        32        4               --              12
  Desautel *et al.*, \[1997\] ([@r15])      39        --        39              --              39
  Hammerer *et al.*, \[1997\] ([@r16])      82        --        41              --              --
  Winters *et al.*, \[1998\] ([@r17])       65        71        3               --              --
  Gomha *et al.*, \[2003\] ([@r18])         61        100       16.3            --              25.6
  Giannantoni *et al.*, 2004 ([@r19])       49        --        61.2 \*(28.6)   38.7 \*(18.4)   --
  Huckabay *et al.*, \[2005\] ([@r20])      60        58        40              --              --
  Kielb *et al.*, \[2005\] ([@r21])         146       65        2               48              14
  Ventimiglia *et al.*, \[2011\] ([@r22])   51        --        63              --              --
  Matsukawa *et al.*, \[2010\] ([@r23])     110       --        33              9               --
  Dubbelman *et al.*, \[2012\] ([@r24])     66        --        26 \*(21.0)     --              --
  Majoros *et al.*, \[2006\] ([@r25])       63        28.6      3.2             --              --

\*, *de novo*. Total N, number of patients. SUI, stress urinary incontinence; DO, detrusor overactivity; DU, detrusor underactivity; PC, poor compliance.

The mainstay of treatment of PPI due to ISD is the insertion of an artificial urinary sphincter (AUS), and male slings. There has been some experience with transurethral injection of bulking agent but generally this is offered only to patients with mild ISD. There are no control trials comparing patients with PPI undergoing urodynamic studies (UDS) *vs.* no UDS prior to AUS insertion. Some papers suggest that the presence of bladder dysfunction does not alter post AUS continence outcomes ([@r26]-[@r29]). It has also been demonstrated that bladder dysfunction may improve after AUS implantation ([@r30]). Nevertheless, AUS placement in those with reduced compliance may lead to upper tract damage ([@r31]). Performing UDS has its advantages as it allows the clinician to assess, treat and counsel those with concurrent bladder dysfunction. If severe bladder dysfunction is identified, treatment of presumptive SUI and its potential complications may be avoided. This can lead to improved quality of life and prevention of complications especially when concurrent treatments of bladder dysfunction may potentially compromise each other.

This review seeks to report the etiology, evaluation, and management of non-urethral post-prostatectomy incontinence. The impact of bladder dysfunction on stress urinary incontinence (SUI) management is also explored. An effort has been made to provide an algorithm to clinicians for appropriate surgical management. The surgical techniques of commonly performed procedures and their outcomes are described.

Methods
=======

A comprehensive literature inquiry using the following medical search engines were performed; PubMed, Ovid, Science Direct and Google Scholar. The search included a combination of the following terms: post-prostatectomy incontinence, DO, DU, impaired compliance, anticholinergic, onabotulinumtoxinA and sacral neuromodulation (SNM). Search results were assessed for their overall relevance to this review. Definitions, general overview and management options were extracted from the relevant medical literature.

Pathophysiology of incontinence post PR
=======================================

The majority of PPI results from ISD which is due to injury to the rhabdosphincter during the apical dissection and denervation of to the neurovascular bundles during RP ([@r6]). Bladder dysfunction, such as DO, DU and impaired bladder compliance can be present before RP, or may arise due to the surgery. Mobilization of the bladder can result in partial autonomic and somatic decentralization as well as inflammation, infection, bladder wall alterations and hypoxia ([@r12],[@r31],[@r32]).

Pre-operative DO can be due to bladder outlet obstruction (BOO) from an enlarged prostate. *De novo* DO may be secondary to BOO from bladder neck contracture or urethral strictures. It is also postulated that DO results from urethral afferent activity when SUI is present. This is believed to be the basis for the reversibility of bladder dysfunction when SUI is successfully treated. Denervation injury to the bladder is the main cause of DU. As for impaired bladder compliance, pelvic surgery such as RP with or without adjuvant radiation therapy can result in bladder fibrosis and contracture, affecting compliance negatively ([@r32]).

Post PR detrusor overactivity
=============================

Incidence of post prostatectomy DO
----------------------------------

DO has been reported to occur at extremely varying rates between 2% and 63% post RP. Kielb *et al.*, found that in patients with PPI, only 2% had DO ([@r21]). Similarly, Majoros *et al.*, found DO in 3.2% of 63 patients with PPI and Winters *et al.*, found DO to be the sole cause of PPI in 3.3% ([@r17],[@r25]). Huckabay *et al.*, and Groutz *et al.*, reported that PPI was due to DO in 13% and 7.2% of patients respectively ([@r12],[@r20]). Differing from these findings, Ventimiglia *et al.*, found DO in 63% with PPI 8--24 months post nerve-sparing RP and considered incontinence to be purely due to DO in 35% of patients ([@r33]). Likewise, Leach *et al.*, established that DO contributed to incontinence in 60% of patients ([@r14]). DO frequently occurs with other bladder dysfunction post RP. Chao *et al.*, found that only 4% of 74 patients with incontinence after prostatectomy had DO alone, while 39% had mixed bladder and sphincter dysfunction ([@r7]). Matsukawa *et al.*, found in patients who underwent UDS before and after laparoscopic RP (LRP), a DO rate of 33% in addition to a DU rate of 9% ([@r23]).

Curiously, RP can affect pre-existing DO in different ways. Constantinou *et al.*, showed that in patients with pre-existing DO, RP did not alter maximum DO pressures ([@r34]). Several studies, however, showed that DO can improve post RP. In a study of 66 patients with PPI, Dubbelman *et al.*, found a pre-operative DO rate of 26% which improved to 21% post RP ([@r24]). Giannantoni *et al.*, found that 61% of patients had pre-existing DO. After 3 years of follow-up, the post RP DO rate was 56%, some of which were de novo ([@r19]). Similarly Matsukawa *et al.*, found that DO disappeared in 54% of patients with pre-existing DO post RP, while 21% of patients developed de novo DO ([@r23]). Comparable results were found by Slova *et al.*, who reported that storage symptoms were significantly improved after open RP ([@r35]). Thus, the natural progression of DO post RP can be variable. Some patients with pre-existing DO report an improvement while others stay the same, and some patients develop post RP *de novo* DO.

Implications of DO in men with SUI
----------------------------------

Men with DO appear to have worse continence outcomes after a retroluminal transobturator (AdVance^®^) sling surgery ([@r36]-[@r38]). Conversely, the presence of DO does not seem to worsen the continence outcome post AUS surgery ([@r27],[@r28]). However, *de novo* or persistent DO related symptoms occur commonly post AUS surgery and a patient needs to be counselled about this ([@r39]).

In general, we believe that it is important to treat DO first. This will have the effect of reducing the overall PPI and may make the component of SUI more apparent. Sometimes, the PPI may improve to the point where the patient may not need their SUI treated ([@r14]), or be treatable with a male sling rather than an AUS.

Management of post prostatectomy DO
-----------------------------------

The management of DO related PPI is determined by its severity and by the presence of ISD, DU and poor compliance (PC). Assessment should comprise of urinalysis, urine culture, 24-hour pad weight, total number of pads, post void residual volume (PVR) and UDS. The subjective impact of PPI may be assessed with a validated questionnaire such as the international consultation on incontinence (ICIQ)---overactive bladder questionnaire.

The three main treatment approaches are similar to non-prostate cancer patients, they are as follows:

1.  ϖ Behavioral therapy (bladder training, biofeedback, pelvic floor muscle therapy, and restricting fluid intake);

2.  ϖ Pharmacologic therapy (anticholinergic and β~3~ agonists);

3.  ϖ Surgical therapy \[Intravesical onabotulinumtoxinA (Botox^®^), SNM, urinary diversion\].

There is a relative deficiency of data reporting the use of anticholinergic medications in post RP patients. However Leach *et al.*, demonstrated that anticholinergics significantly decreased pad score in patient with DO prior to AUS insertion ([@r14]). Mirabegron, the selective β3 agonist, has similar efficacy to anticholinergics but with less side effects, that may benefit patients with PPI DO. But there is no data reported of its use in the post RP population.

Surgical treatments include intravesical Botox^®^, SNM, and as a last resort, urinary diversion. Intravesical Botox^®^ has an efficacy rate of 30--86% ([@r40]-[@r42]). However, Botox has a limited duration of benefit and repeat treatments are needed. There is also a significant risk of urinary retention (about 5%) and the patient may be required to perform clean intermittent self-catheterization (CISC) ([@r43]). Intravesical Botox may be an unattractive treatment if AUS is planned, as repeated cystoscopy or CISC may increase the risk of cuff erosion.

SNM is an alternative to intravesical Botox^®^ on theoretical grounds. At this stage there are relatively few data about SNM in post RP population. For DO generally, SNM has a success rate of 53% to 80% ([@r44]-[@r46]). SNM does not cause retention and may treat the other forms of bladder dysfunction that can be found in association with DO, in particular DU, with success rates of 66.7% to 87.4% ([@r47]). Thus, SNM is potentially preferable to intravesical Botox^®^ in treating post PR DO.

For severe refractory DO post RP, continued pad use or major open surgery may be the only options remaining. Augmentation cystoplasty is associated with high rates of CISC (75%) ([@r48]), and is not recommended, as this increases the risk of device urethral erosion. Creation of a urinary diversion remains another viable option, particularly in patients who might be deemed unsuitable for reconstructive bladder surgery ([@r49]). These treatments must be seen as a last resort.

Post prostatectomy DU
=====================

Incidence and diagnosis of post prostatectomy DU
------------------------------------------------

The International Continence Society (ICS) defines DU as "*a contraction of reduced strength and/or duration*, *resulting in prolonged bladder emptying and/or failure to achieve complete bladder emptying within a normal time span*" ([@r50]). Some patients have pre-existing DU and others develop it *de novo* ([@r7]), mainly as a result of denervation injury during the RP. Interestingly Chung *et al.*, postulated that minimally invasive surgery has a higher risk of causing DU as it involves a posterior approach to the dissection of the seminal vesicles where the pelvic nerves are situated. During an open RP, dissection is preformed closer to the seminal vesicles due to traction on the prostate, sparing nerves at the base of the bladder ([@r51]). In the community, the prevalence of DU is about 9% to 23% in men less than 50 years, increasing to about 48% in men older than 70 ([@r52]). Post RP DU appears to be common; Chung *et al.* reported that 41% of patient post RP had DU ([@r51]). Similarly, Porena *et al.*, found DU in 29--61% of patients post RP, of which 47% are *de novo* ([@r32]).

Studies reporting the incidence of DU post RP have limitations. Firstly, there is no consensus on which urodynamic method should be used to diagnose DU. Described methods include the Bladder Contractility Index (BCI), the presence of abdominal straining during voiding and arbitrary urodynamic cutoffs such as PdetQmax \<20 cmH~2~O or a Qmax \<15 mL/sec. PdetQmax in men with ISD may be falsely low due to reduced urethral resistance and formulas based on this may be inaccurate to diagnose DU ([@r53]). Isometric detrusor contraction pressure (Piso) may be a more accurate method to diagnose DU. It is measured by gently occluding the penile urethra during voiding, with a Piso of less than 50 cmH~2~O being diagnostic of DU ([@r53]). Secondly, not all studies compared pre and post op urodynamics findings, and therefore the true effect of RP on detrusor contractility is not fully appreciated.

Implications of DU in men with SUI
----------------------------------

Men with DU often void with abdominal straining due to insufficient detrusor strength. This can also be a learned behavior, as patients with decreased sphincteric resistance may find it easier and faster to void by straining ([@r12]). Therefore some concern exists in placing a male sling to treat SUI in men with DU, as the sling is designed to create a fixed resistance and may cause urinary retention. One study tried to alleviate some of these concerns. Han *et al.*, examined 50 patients with DU *vs.* 42 patients with normal contractility who had sling procedures. They found no significant differences in post sling PVR and Patient Global Impression of Improvement (PGI-I). In addition, there were no differences in those who were valsalva voiders (Pabd \>20 cmH~2~O during voiding) *vs.* normal voiders ([@r54]). The authors concluded that placing a male sling in these patients with DU was safe, but we certainly need more similar studies to confirm this.

Regarding the choice of male sling in DU patients, the retroluminal transobturator sling (AdVance sling^®^) offers an advantage over the more compressive quadratic sling (Virtue sling^®^) ([@r55]). The AdVance^®^ sling acts by relocating the bulbar urethra and causes minimal compression, whereas the compressive quadratic Virtue sling^®^ is typically tensioned to a pressure of 60 cmH~2~O. DU patients may not be able to generate this pressure and may not be able to void ([@r56]).

Placing an AUS in patients with DU or who are Valsalva voiders post RP appears to be safe and effective. The cuff is cycled open with relief of obstruction during voiding. Studies have demonstrated no increased risk of raised PVR or urinary retention post AUS in these patients ([@r18],[@r57]). As DU can present with both voiding and storage symptoms, patients still have to be counselled post SUI surgery about the possibility of persistence of common DU symptoms including urgency, weak stream, straining to void, and nocturia ([@r58]).

Management of post prostatectomy DU
-----------------------------------

If a patient is able to empty well during voiding after SUI surgery, he can be advised to continue to do double voiding or use abdominal straining. If there is decreased bladder sensation, the patient may have to do timed voiding. In patients who have pre RP DU or in those with an acontractile bladder who are not able to empty the bladder even with abdominal straining, it is anticipated they may have to continue or start doing CISC even after SUI surgery. It is not advisable to perform CISC through a urethral AUS cuff due to the high risk of erosion. A bladder neck AUS cuff is also not recommended as it is considered technically difficult and risky in a post RP patient where the anastomotic area may be scarred.

In this setting, an adjustable transobturator male sling (ATOMS^®^) may be considered although there has been no published data about this. Unlike the AUS which circumferentially compresses the urethra, the ATOMS^®^ only compresses the bulbar urethra dorsally, leaving the ventral and lateral blood supply intact. The bulbospongiosus muscle is also left intact and acts as an additional protective layer between the device and the urethra. Hoda *et al.*, reported no case of urethral erosion in their series of 99 patients with ATOMS^®^ with a mean follow-up of 17.8 months, although no patient needed to do CISC ([@r59]). In an abstract, Law *et al.* reported on one patient who needed to start CISC three times a day, in their series of eight patients who were implanted with the ATOMS^®^, and there was no device erosion in that patient ([@r60]).

SNM is an option for patients with DU. A meta-analysis by Gross *et al.*, found that patients with DU had statistically significant increase in voided volume and a decrease in mean PVR after SNM treatment ([@r61]). In the non RP population the place of SNM in DU is well established. SNM is an effective treatment option for DU with excellent success rates. However, there are currently no published data on SNM in patients with post RP DU. Further research may demonstrate the place of SNM in patients with mixed PPI. If the DU can be successfully treated with SNM first, it may obviate the need for CISC, and simplify the subsequent treatment of the SUI.

Post prostatectomy impaired bladder compliance
==============================================

Incidence of post prostatectomy impaired bladder compliance
-----------------------------------------------------------

Bladder compliance is calculated by dividing the volume change (ΔV) by the change in detrusor pressure (ΔPdet) during that change in volume (mL/cmH~2~O). The ICS recommends two standard points be used for determination of compliance, firstly the detrusor pressure at the start of bladder filling and secondly, the detrusor pressure at cystometric capacity or before the start of any detrusor contraction ([@r51]). Poor bladder compliance, is defined as significant increases in Pdet with small increments in bladder volume and may lead to incontinence and damage of the upper urinary tract ([@r62],[@r63]). Various definitions and bladder pressure criterion have been advocated for poor compliance. Chou *et al.*, recommend \<10 mL/cmH~2~O ([@r64]). Weld *et al.*, reported higher incidences of upper tract damage and vesicoureteral reflux in the spinal cord injury population with bladder compliance of \<12.5 mL/cmH~2~O ([@r65]), while others suggest \<20 mL/cmH~2~O as poor compliance ([@r66]).

Several studies have examined for impaired compliance in patients with PPI. Ficazzola *et al.*, found that impaired bladder compliance was present in 5% ([@r6]). Conversely, Giannantoni *et al.*, reported that 28.1% of patients demonstrated evidence of impaired bladder compliance which was defined as change in detrusor pressure of 20 mL/cmH~2~O at 3 years post RP ([@r66]). Gomha *et al.*, noted approximately 24.6% of patients demonstrated impaired compliance, of which 9.8% had PC (defined as \>10 mL/cmH~2~O) ([@r18]). While there seems to be variation in the reported incidence of impaired compliance after RP, it certainly is something that should be borne in mind by the clinician. It must be noted that impaired compliance in severely incontinent patients with ISD may be artefactual, due to supra-physiologic filling of chronically under filled bladders during urodynamics, and may be over reported.

Management of post prostatectomy impaired bladder compliance
------------------------------------------------------------

Impaired or poor bladder compliance can be managed with observation and conservative measures such as timed voiding, anticholinergics, beta-3-agonists, or intravesical Botox^®^ ([@r28]). Anticholinergics medications are effective in increasing bladder capacity, decreasing bladder filling pressure, and improving bladder compliance ([@r67]-[@r69]). In addition to improving compliance, Watanabe *et al.*, demonstrated improved hydronephrosis and vesicoureteral reflux with anticholinergics ([@r70]). Similarly, mirabegron a β3-adrenoceptor agonist, improves cystometric capacity and bladder compliance, and it lowers vesicoureteral reflux grade in patients with the poorly compliant bladder and is an option for those who are intolerant of anticholinergics ([@r71]). Intravesical Botox has been indirectly used to treat PC in several studies examining the effect of Botox^®^ on DO. In addition to increasing bladder capacity, Botox^®^ has been shown to improve bladder compliance ([@r70],[@r72]-[@r74]).

In the setting of PPI, when SUI surgery is considered, bladder compliance becomes an important consideration. Any procedure that obstructs the bladder outlet such as male sling or AUS could increase bladder pressure that may be transmitted to the upper tracts, potentially placing the kidneys at risk. Appropriate management of impaired compliance with the goal of reducing bladder pressures should be advocated prior to undertaking SUI surgery. Treatments should be evaluated with repeat urodynamics to assess for treatment success, and to ensure that SUI surgery can proceed without undue risk of upper urinary tract deterioration over the long-term.

Implications of impaired compliance in men with SUI
---------------------------------------------------

There is limited data in the literature about the safety of a male sling in terms of upper tract and renal function preservation in patients with poor bladder compliance. Logically, a tight compressive sling (quadratic Virtue sling^®^) may be contraindicated and a non-occlusive sling may be safer. Habashy *et al.* reported on 20 patients with PC who had the AdVance^®^ sling, and PC is not predictive of worse continence outcome. However, they did not report on the post-sling incidence of renal failure or hydronephrosis ([@r36]).

It is still unknown if poor bladder compliance is an absolute contraindication to AUS surgery in the non-neurogenic, non-irradiated patient population. There appears to be a tendency towards worse continence results in those with impaired compliance on pre-operative urodynamic studies ([@r28]). Other studies, however, have failed to corroborate these findings ([@r12],[@r27]). Preservation of continence status post AUS surgery may also be an ominous sign of potential upper tract damage ([@r28]). While no safe cutoff detrusor pressures for the implantation of AUS has been established, patients with mildly impaired bladder compliance may still undergo insertion of an AUS. In these patients, long-term follow-up of the upper tracts with periodic serum creatinine measurement, and renal ultrasound should be employed to screen for upper urinary tract deterioration ([@r75]). These patients may also be advised to do timed voiding in order to avoid reaching the threshold bladder volumes that result in high bladder pressures. There remains a subset of patients with persistently elevated detrusor pressures, or cannot be relied upon to do timed voiding, or have evidence of pre-existing renal impairment/hydronephrosis, who ultimately may not be suitable for SUI surgery. These patients should be counseled accordingly, as the PPI may be serving as a "pop-off" mechanism, protecting their upper tracts.

Conclusions
===========

SUI remains the most common cause of PPI, but bladder dysfunction in the form of DU, DO and PC are important causes of PPI that must not be ignored. All can occur pre RP or can arise *de*-*novo* and can exist alone or in combination with SUI. Bladder dysfunction can affect the outcome of SUI surgery, thus each patient must be treated on an individual basis. Patients with SUI and DO are recommended to have their DO treated first. Patients with DU and SUI must be counselled that they may not be able to void after sling surgery. Patient with PC may need their compliance treated to prevent upper tract damage prior to SUI surgery.
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